Phyla

Phyla is developing alternative therapies for antibiotics. The focus of most microbiome efforts is to discover beneficial bacteria to add to the microbiome, in order to cure disease or maintain health. However others lack a subtractive function that can remove harmful or disease-causing bacteria, that would allow the microbiome to rebalance and achieve a stable healthy state. Using bacteriophages as a foundation, they are developing a powerful platform that allows us to selectively 'subtract' bad bacteria without harming the good strains present in the community. It's a bit like using a sniper instead of a grenade to take out a bad guy in a crowd of people.

Phyla headquartered in United States, North America, operates in the Biotechnology, Health Care, Wellness sector. The company focuses on Biotechnology and has secured $232.9M in funding across 72 round(s). With a team of 1-10 employees, Phyla is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Phyla, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.